GeneCopoeia Lentifect SARS-CoV-2 Spike-pseudotyped lentivirus

Saturday, 01 August, 2020 | Supplied by: United Bioresearch Products Pty Ltd


..jpg

GeneCopoeia’s Lentifect SARS-CoV-2 Spike-pseudotyped lentivirus products are designed to produce a specially packaged variant of standard lentivirus that replaces VSV-G envelope glycoprotein with the Spike (S) protein.

The company’s spike-pseudotyped lentivirus can be used for several applications, such as: vaccine development for the SARS-CoV-2 virus; studying the efficacy and mechanism of neutralising antibodies against the SARS-CoV-2 virus; development of antiviral therapeutic agents; and studying the mechanism of virus-receptor interaction.

In addition to lentiviral particles, GeneCopoeia also offers a SARS-CoV-2 Spike Protein Pseudotyped Lentivirus Particle Kit that includes all required reagents: Lentifect SARS-CoV-2 Spike protein-pseudotyped lentiviral particles; Lentifect Standard VSV-G lentiviral particles; and the company’s ACE2-expressing HEK293T cell line.

For more information: https://www.genecopoeia.com/product/lentifect-sars-cov-2-spike-pseudotyped-lentivirus/.

Online: www.unitedbioresearch.com.au
Phone: 02 4575 0309
Related Products

Matreya phosphosphingolipids for lipidomics research

Matreya offers an extensive list of phosphosphingolipids including sphingomyelins,...

CellSera foetal bovine serum

CellSera's foetal bovine serum is sterile filtered using Sartorius Stedim Biotech triple 0.1...

Novozymes Remify Everis 100 L enzyme solution for surgical device cleaning

The product is a phosphodiesterase (PDE) — a nuclease — that speeds up reactions and...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd